doi: 10.1161/01.ATV.0000222960.43792.ff
© 2006 American Heart Association, Inc.
Editorials |
Lipoxygenase Pathways as Mediators of Early Inflammatory Events in Atherosclerosis
From the Departments of Physiology and Biochemistry, Queen’s University, Kingston, Canada.
Correspondence to Colin Funk, Department of Physiology, Stuart Street, Queen’s University, Kingston, ON K7L 3N6 Canada. E-mail funkc{at}post.queensu.ca
Oxidative modification of low density lipoproteins has been a leading hypothesis in atherogenesis, and throughout the 1990’s there was intense interest in the discovery of pathways leading to this modification.1,2 In a commentary to an article dealing with 12/15-lipoxygenase gene disruption in the atherosclerotic apolipoprotein E (apoE)-deficient mouse model in 1999, Daniel Steinberg declared "at last direct evidence that lipoxygenases play a role in atherosclerosis."3,4 Since this article seven years ago, the lipoxygenase pathway involvement in atherogenesis has become rather more complicated.
See page 1260
Lipoxygenases are non-heme iron–containing enzymes that catalyze the stereospecific incorporation of molecular oxygen into polyunsaturated fatty acids with a 1,4-cis, cis-pentadiene motif.5 With respect to atherosclerosis 2 of the 6 (human)/7 (mice) lipoxygenase family members have received the most attention because of their expression patterns in inflammatory cells and in some settings within endothelial cells; these are the 12/15-lipoxygenase (12/15-LO; also known as the leukocyte-type 12-lipoxygenase and 15-lipoxygenase-1) and 5-lipoxygenase.6,7 12/15-LO catalyzes the transformation of free arachidonic acid to 12-hydroperoxy-eicosatetraenoic acid (12-HPETE) and 15-HPETE. These products are reduced to the corresponding hydroxy derivatives 12-HETE and 15-HETE by cellular peroxidases. Mice make predominantly 12-HETE whereas humans produce mainly 15-HETE. Both human and mouse 12/15-LO enzymes metabolize linoleic acid to 13-hydroperoxy-octadecadienoic acid (13-HPODE; the reduced product is 13-HODE) as well as metabolizing more complex lipids including cholesteryl linoleate and sn2 polyunsaturated fatty acids within phospholipids. Thus, 12/15-LO has been shown to oxidatively modify the key lipid components of LDL. 5-Lipoxygenase, on the other hand, only metabolizes free arachidonic acid leading to the formation of proinflammatory leukotrienes and cannot participate in the direct oxidative modification of LDL.6,7
The ability to generate oxidatively-modified LDL by 12/15-LO is only one potential mechanism for its atherogenic promoting role. 12/15-LO can also modulate the expression of a key proinflammatory proatherosclerotic Th1 cytokine, interleukin (IL)-12.8 Hedrick and colleagues9–11 have been following a line of studies over the past 7 years indicating that 12/15-LO can also enhance the adhesion of monocytes to endothelial cells, an early event in atherogenesis. In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, these researchers further our understanding of the intracellular pathways involved in the 12/15-LO-mediated monocyte adhesion events.12 Using 12/15-LO knockout mice cross-bred to apoE-deficient mice, they demonstrate a dramatic reduction of monocyte binding to endothelial cells derived from these mice. A lipoxygenase inhibitor, CDC (cinnamyl-3,4-dihydroxy-
-cyanocinnamate), mimics the effect observed by gene disruption. The monocyte adhesion appears to be mediated primarily by intercellular adhesion molecule-1 (ICAM-1), and previous work by this group9 also demonstrated the importance of the fibronectin isoform containing connecting segment-1 in monocyte adhesion. Here, and in another recent publication,11 they show that the 12/15-LO product, 12(S)-HETE, but not the stereoisomer 12(R)-HETE, mediates the ICAM-1 induction through a G protein (G12/13), RhoA, protein kinase C, NF-
B activation pathway (see the Figure). The authors postulate that the 12/15-LO product can activate a G protein–coupled receptor (GPCR) to initiate these events. The isolation of this receptor has proven elusive. With the full complement of human GPCRs cloned and expressed it is surprising that no research group has "adopted" one of the orphan members as a 12-HETE receptor. Others have demonstrated the capacity of 12-HETE to bind an intracellular receptor that complexes with other proteins, which is more reminiscent of nuclear hormone signaling.13,14 In any case, knowing the pathway of activation from 12-HETE synthesis to ICAM-1 induction and monocyte adhesion is a significant step forward in determining molecular eicosanoid signaling translated to vascular biological activities. The authors’ work with both 12/15-LO overexpressing endothelial cells from transgenic mice10,11 and experiments with 12/15-LO deficient mouse-derived endothelial cells12 provide a compelling argument for this mode of signaling.
|
4:1 ratio and is the likely ligand for activation of a putative HETE receptor and signaling through the G protein G12/13 to a pathway consisting of RhoA, protein kinase C, and nuclear factor The next important step will be to establish the connection between the enhanced ICAM-1 induction by 12(S)-HETE and atherogenesis. The case for ICAM-1 involvement in mediating early atherogenic events is unclear with some groups reporting that ICAM-1 deficiency reduces lesion development in apoE-deficient mice,15,16 whereas another team of investigators contends evidence that vascular cell adhesion molecule (VCAM)-1, but not ICAM-1, is important in early atherogenesis.17 Returning to the complicated area of lipoxygenases in atherosclerosis mentioned in the first paragraph, the role for 12/15-LO in atherogenesis has been verified in three different mouse models (apoE, LDL-R, and apobec-1/LDL-R deficiency) by at least three research groups and studies suggest a role for 12/15-LO expressing bone marrow–derived cells (eg, macrophages) in preference to endothelial cells in the proatherogenic role.4,8,18,19 However, other investigators have shown that the human 15-LO pathway and transgenic 15-LO macrophage overexpressing rabbits may contribute antiinflammatory compounds like lipoxins and lead to a reduction in atherosclerosis.20,21 To further complicate matters there have been a substantial number of studies in the past few years implicating the 5-LO pathway in atherogenesis in humans and mice with a large number of inconsistencies between studies (reviewed in refs. 22, 23). 5-LO–derived leukotriene B4 appears to influence early atherosclerotic events in mouse studies perhaps also by mediating monocyte adhesion and recruitment via monocyte chemoattractant protein-1 (MCP-1).24–27 However, lesion development resulting from complete loss of leukotriene biosynthesis (both LTB4 and the cysteinyl leukotrienes LTC4, LTD4, and LTE4) does not appear to substantially impact atherosclerosis in a variety of fat feeding and mid-to-long–term experiments in both apoE- and LDL-R–deficient states.28
Integrating the biological activities of the 5-LO and 12/15-LO pathways into a unified paradigm for early atherogenic events should be the goal for researchers in this area over the next few years. Hedrick and colleagues’ experiments to elucidate the intracellular signaling events in the 12/15-LO pathway are important steps forward toward this goal.
 |
Acknowledgments |
|---|
This work was supported by grants from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Ontario. C.F. is a holder of a Tier I Canada Research Chair in Molecular, Cellular, and Physiological Medicine and Career Investigator Award from the Heart and Stroke Foundation of Canada.
|
References |
|---|
 Top References |
|---|
1. Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med. 1992; 43: 219–225.[CrossRef][Medline] [Order article via Infotrieve]
2. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996; 20: 707–727.[CrossRef][Medline] [Order article via Infotrieve]
3. Steinberg D. At last, direct evidence that lipoxygenases play a role in atherogenesis. J Clin Invest. 1999; 103: 1487–1488.[Medline] [Order article via Infotrieve]
4. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of 12/15-lipoxygenase results in inhibition of atherosclerotic lesion development in mice lacking apolipoprotein E. J Clin Invest. 1999; 103: 1597–1604.[Medline] [Order article via Infotrieve]
5. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999; 274: 23679–23682.
6. Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med. 2004; 14: 191–195.[CrossRef][Medline] [Order article via Infotrieve]
7. Zhao, L, Funk, C.D. Lipoxygenases: potential therapeutic target in atherosclerosis, pp. 207–218. In: Advances in Translational Medical Science; Lipids and Atherosclerosis, eds. Packard CJ, Rader DJ. London: Taylor and Francis; 2006.
8. Zhao L, Cuff CA, Moss E, Wille U, Cyrus T, Klein EA, Pratico D, Rader DJ, Hunter CA, Pure E, Funk CD. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem. 2002; 277: 35350–35356.
9. Patricia MK, Kim JA, Harper CM, Shih PT, Berliner JA, Natarajan R, Nadler JL, Hedrick CC. Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arterioscler Thromb Vasc Biol. 1999; 19: 2615–2622.
10. Reilly KB, Srinivasan S, Hatley ME, Patricia MK, Lannigan J, Bolick DT, Vandenhoff G, Pei H, Natarajan R, Nadler JL, Hedrick CC. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem. 2004; 279: 9440–9450.
11. Bolick DT, Orr AW, Whetzel A, Srinivasan S, Hatley ME, Schwartz MA, Hedrick CC. 12/15-lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB. Arterioscler Thromb Vasc Biol. 2005; 25: 2301–2307.
12. Bolick DT, Srinivasan S, Whetzel A, Fuller LC, Hedrick CC 12/15 Lipoxygenase mediates monocyte adhesion to aortic endothelium in apolipoprotein E-deficient mice through activation of RhoA and NFB. Arterioscler Thromb Vasc Biol. 2006; 26: 1260–1266.
13. Herbertsson H, Kuhme T, Hammarstrom S. The 650-kDa 12(S)-hydroxyeicosatetraenoic acid binding complex: occurrence in human platelets, identification of hsp90 as a constituent, and binding properties of its 50-kDa subunit. Arch Biochem Biophys. 1999; 367: 33–38.[CrossRef][Medline] [Order article via Infotrieve]
14. Kurahashi Y, Herbertsson H, Soderstrom M, Rosenfeld MG, Hammarstrom S. A 12(S)-hydroxyeicosatetraenoic acid receptor interacts with steroid receptor coactivator-1. Proc Natl Acad Sci U S A. 2000; 97: 5779–5783.
15. Bourdillon MC, Poston RN, Covacho C, Chignier E, Bricca G, McGregor JL. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(–/–)/ICAM-1(–/–)) fed a fat or a chow diet. Arterioscler Thromb Vasc Biol. 2000; 20: 2630–2635.
16. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2000; 191: 189–194.
17. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001; 107: 1255–1262.[Medline] [Order article via Infotrieve]
18. George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation. 2001; 104: 1646–1650.
19. Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T, Forlow SB, Stark MA, Smith DF, Clarke S, Srinivasan S, Hedrick CC, Pratico D, Witztum JL, Nadler JL, Funk CD, Ley K. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004; 110: 2024–2031.Erratum in: Circulation. 2004;110:3156.
20. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001; 2: 612–619.[CrossRef][Medline] [Order article via Infotrieve]
21. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, Guevara NV, Chan L. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest. 1996; 98: 2201–2208.[Medline] [Order article via Infotrieve]
22. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov. 2005; 4: 664–672.[CrossRef][Medline] [Order article via Infotrieve]
23. Lotzer K, Funk CD, Habenicht AJ. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim Biophys Acta. 2005; 1736: 30–37.[Medline] [Order article via Infotrieve]
24. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002; 22: 443–449.
25. Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004; 24: 369–375.
26. Heller EA, Liu E, Tager AM, Sinha S, Roberts JD, Koehn SL, Libby P, Aikawa ER, Chen JQ, Huang P, Freeman MW, Moore KJ, Luster AD, Gerszten RE. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation. 2005; 112: 578–586.
27. Huang L, Zhao A, Wong F, Ayala JM, Struthers M, Ujjainwalla F, Wright SD, Springer MS, Evans J, Cui J. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol. 2004; 24: 1783–1788.
28. Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, Kaiser B, John N, Schmidt S, Spanbroek R, Lotzer K, Huang L, Cui J, Rader DJ, Evans JF, Habenicht AJ, Funk CD. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004; 10: 966–973.[CrossRef][Medline] [Order article via Infotrieve]
Related Article:
B
Arterioscler. Thromb. Vasc. Biol. 2006 26: 1260-1266.
This article has been cited by other articles:
 |
|
 |
|
  C. S. Nunemaker, M. Chen, H. Pei, S. D. Kimble, S. R. Keller, J. D. Carter, Z. Yang, K. M. Smith, R. Wu, M. H. Bevard, et al. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by western diet Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1065 - E1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Uozumi, Y. Kita, and T. Shimizu Modulation of Lipid and Protein Mediators of Inflammation by Cytosolic Phospholipase A2{alpha} during Experimental Sepsis J. Immunol., September 1, 2008; 181(5): 3558 - 3566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Agrawal, M. Febbraio, E. Podrez, M. K. Cathcart, G. R. Stark, and G. M. Chisolm Signal Transducer and Activator of Transcription 1 Is Required for Optimal Foam Cell Formation and Atherosclerotic Lesion Development Circulation, June 12, 2007; 115(23): 2939 - 2947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. McCormick, D. Gavrila, and N. L. Weintraub Role of Oxidative Stress in the Pathogenesis of Abdominal Aortic Aneurysms Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 461 - 469. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||